Clinical trials: KSHV
KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Background: Kaposi sarcoma herpesvirus (KSHV)-associated inflammatory cytokine syndrome (KICS) and KSHV-multicentric Castleman disease (MCD) occur in people living with HIV.
- Trial name
- NCT06052618
- Testing
- Pacritinib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Kaposi s Sarcoma (KS)
Studies of Human Herpesvirus 8 and Kaposi's Sarcoma in Sicily
A series of studies will be conducted in Sicily by a collaborative team from the U.S. National Cancer Institute and the University of Palermo to better understand the prevalence and risk factors for the newly discovered human…
- Trial name
- NCT00339937
- Where
- Italy
- Volunteers
- 4,622 people
- Sponsor
- National Cancer Institute (NCI)
HIV, AIDS
HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT
Kaposi's sarcoma (KS)is the commonest malignancy associated with HIV/AIDS. Therapy for this cancer, which causes substantial morbidity, is suboptimal in resource poor settings.
- Conditions
- HIV, AIDS, Kaposi's Sarcoma, Human Herpesvirus 8
- Trial name
- KAART (NCT00380770)
- Testing
- Generic HAART Triomune : d4T, 3TC, NVP, Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
- Where
- South Africa
- Volunteers
- 112 people
- Sponsor
- University of KwaZulu
Giant Lymph Node Hyperplasia
Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
The purpose of the study is to learn whether people who are experiencing an MCD (multicentric Castleman's Disease) flare will improve after taking valganciclovir.
- Trial name
- NCT00361933
- Testing
- Valganciclovir
- Sponsor
- University of Washington
HHV8, HHV8 Infection
HHV8 and Solid Organ Transplantation
Solid organ transplant candidates will undergo serological screening for HHV8 at time of listing and transplantation. In the event of a recipient/donor mismatch R-/D+ or in the presence of a seropositive recipient (R+), blood…
- Conditions
- HHV8, HHV8 Infection, HHV8-Related Malignant Neoplasm, Kaposi Sarcoma
- Trial name
- NCT05081141
- Testing
- Diagnostic test for HHV8 exposure
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Kaposi's Sarcoma, HHV-8
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
Background: Kaposi's sarcoma (KS) is a disease in which cancer cells are found in the tissues under the skin or mucous membranes that line the mouth, nose, and anus.
- Conditions
- Kaposi's Sarcoma, HHV-8, KSHV
- Trial name
- NCT00287495
- Testing
- BAY 43-9006
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Castleman Disease, Multicentric Castleman Disease
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Background: Kaposi's sarcoma-associated herpes virus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is caused by a herpes virus known as KSHV.
- Conditions
- Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
- Trial name
- NCT01441063
- Testing
- Zidovudine, Tocilizumab, Valganciclovir (VGC)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00598169
- Testing
- rituximab, bortezomib, carboplatin
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- AIDS Malignancy Consortium
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Prospective Study of Lymphoproliferative Diseases
This study will help researchers learn more about non-Hodgkin's lymphoma and Hodgkin's lymphoma and how it is treated in Kenya. Researchers want to see if having certain viruses like Epstein Barr Virus (EBV), Human…
- Trial name
- NCT01704742
- Where
- 2 sites in United States, Kenya
- Sponsor
- West Virginia University
Kaposi Sarcoma
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Background: Kaposi sarcoma (KS) is a cancer that causes abnormal tissue to grow in the skin, lymph nodes, and other organs. KS is caused by a virus known as Kaposi sarcoma herpesvirus.
- Trial name
- NCT07308886
- Testing
- CYT107
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Kaposi Sarcoma
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Background: Kaposi Sarcoma (KS) is common in people with human immunodeficiency virus (HIV) but can also occur in people who do not have HIV.
- Trial name
- NCT04941274
- Testing
- Abemaciclib
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
AIDS-Related Kaposi Sarcoma, HIV Infection
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
This pilot, phase I trial studies the side effects and best dose of bortezomib in treating patients with acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma that has come back or has not responded to treatment.
- Conditions
- AIDS-Related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma
- Trial name
- NCT01016730
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond to treatment (refractory).
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Trial name
- NCT03038672
- Testing
- Nivolumab, Varlilumab
- Where
- 33 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP])…
- Conditions
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Trial name
- NCT04799275
- Testing
- Biospecimen Collection, Computed Tomography, Cyclophosphamide
- Where
- 176 sites in United States
- Volunteers
- 422 people
- Sponsor
- National Cancer Institute (NCI)
Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion Lymphoma
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
Background: The chemotherapy combination DA-EPOCH-RP includes the drugs etoposide (E), prednisone (P), vincristine (O), cyclophosphamide (C), doxorubicin (H), rituximab (R), and pomalidomide (P).
- Trial name
- NCT02228512
- Testing
- Pomalidomide, Rituximab, Prednisone
- Sponsor
- National Cancer Institute (NCI)
Kaposi's Sarcoma
Risk Factors for Non-HIV-Related Kaposi s Sarcoma
This study will try to identify risk factors for Kaposi s sarcoma, a rare skin cancer, and to understand the role of the KSHV virus in development of the disease.
- Trial name
- NCT00339326
- Where
- Italy
- Volunteers
- 1,383 people
- Sponsor
- National Cancer Institute (NCI)
Kaposi's Sarcoma, HIV Infections
Anti-Retrovirals for Kaposi's Sarcoma
The primary purpose of this study is to determine whether a protease inhibitor-based antiretroviral regimen is more efficacious than a non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimen in promoting the…
- Trial name
- ARKS (NCT00444379)
- Testing
- Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
- Where
- Uganda
- Volunteers
- 224 people
- Sponsor
- University of California, San Francisco
Dilated Cardiomyopathy, Kaposi's Sarcoma-Associated Herpesvirus Infection
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.
- Trial name
- SDCMK (NCT06236022)
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Tongji Hospital
Kaposi's Sarcoma, Herpesviridae Infection
Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States
This study will investigate patterns of Kaposi's sarcoma herpes virus (KSHV) in the United States and its potential impact on the U.S. population.
- Trial name
- NCT00026728
- Where
- United States
- Volunteers
- 20,169 people
- Sponsor
- National Cancer Institute (NCI)
Human Herpesvirus 8
Suppression of Oral HHV8 Shedding With Valganciclovir
The purpose of the study is to use valganciclovir to define the role of antiviral therapy in suppression of HHV-8 shedding in HHV-8 seropositive men.
- Trial name
- NCT00194467
- Testing
- valganciclovir
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Washington